| Identification | Back Directory | [Name]
(R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1- carboxylic acid methyl ester | [CAS]
1256756-88-3 | [Synonyms]
SP-2086
CPDA1089
RetagliptinPhosphate
RETAGLIPTIN; SP-2086
SP-2086,Retagliptin Phosphate,DPP-4,SP2086,inhibit,GLP-1,T2DM,Retagliptin,DPP,Inhibitor,Dipeptidyl Peptidase
methyl (R)-7-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylate phosphate
(R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1- carboxylic acid methyl ester | [Molecular Formula]
C19H18F6N4O3 | [MDL Number]
MFCD31692418 | [MOL File]
1256756-88-3.mol | [Molecular Weight]
464.362 |
| Hazard Information | Back Directory | [Uses]
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research[1]. | [IC 50]
DPP-4 | [storage]
Store at -20°C | [References]
[1] Hu C, et al. Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49(1):74-80. PMID:29737094
[2] Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. DOI:10.1080/14728214.2016.1257608 |
|
|